
News|Articles|October 5, 2026
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
Author(s)Sheryl Stevenson
Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.
Advertisement
Advertisement
The Nobel Assembly at Karolinska Institutet announced that the 2026 Nobel Prize in Physiology or Medicine will be shared equally among Karl Deisseroth, MD, PhD, of the Howard Hughes Medical Institute and Stanford University; Peter Hegemann, PhD, of Humboldt University of Berlin; and Georg Nagel, PhD, of the University of Würzburg, “for their discoveries concerning light-gated ion channels and optogenetics.”¹ The prize carries 12 million Swedish kronor—approximately US $1.2 million at current exchange rates—to be split equally among the three laureates.¹
Related to this article

VeonGen aligns with FDA on phase 3 design for VG801, a dual-AAV Stargardt gene therapy, after uncontrolled phase 1/2 BCVA gains.

The FDA approved Lucamzi (ranibizumab-blrz), Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.

Josef Huemer, MD, discusses retinal changes linked to atrial fibrillation and what they mean for eye care clinicians.

The first-in-human study of the GalNAc-conjugated siRNA joins a fast-moving Stargardt pipeline as the FDA weighs the first potential approval for the disease.

The agency concluded that GLP-1 receptor agonists carry a potential increased risk of the rare optic neuropathy and is adding it to the Warnings and Precautions section of every product's label.

From the first BLA acceptance for a gene-agnostic optogenetic therapy to the first pivotal gene therapy trial in geographic atrophy, these are the retinal gene therapy milestones of 2026.
Advertisement
Advertisement


